Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...

Epileptic seizures alter sleep by prolonging the stage that's central to memory formation, potentially predisposing the brain ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

Xenon Pharmaceuticals Inc. XENE-Q generated positive results from a critical late-stage human trial for its epilepsy ...

A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among those deemed “treatment sensitive,” 69.4% ...

A pioneering gene therapy could help treat a rare seizure disorder called Dravet syndrome, according to new clinical trial ...

Like many teenagers, Danielle Holton's first car was a ticket to freedom. At age 17, she bought a used Hyundai wagon from her mom, paying for it with money from her job as a certified nursing ...

—After ruling out seizure mimics and seizures caused by an acute trigger, the remaining patients with unprovoked seizure require a further assessment. Here are some details. Reviewed by Aaron Miller, ...

Epilepsy is one of the most common neurological conditions, affecting more than 65 million worldwide. For those dealing with epilepsy, the advent of a seizure can feel like a ticking time bomb. It ...